Objective. To study the role of B lymphocytes in systemic sclerosis (SSc).
patients with dcSSc and those with lcSSc. Peripheral B lymphocytes from SSc patients secreted both IL-6 and TGFb, and they activated fibroblasts in vitro.
Systemic sclerosis (SSc) is a connective tissue disease characterized by fibroblast activation, increased extracellular matrix synthesis, and vascular remodeling (1) . Activation of fibroblasts and endothelial cells, together with increased oxidative stress, represent the hallmarks of SSc pathogenesis. SSc is classified according to the extent of skin involvement as either limited cutaneous SSc (lcSSc), with skin lesions essentially limited to the hands and face, or diffuse cutaneous SSc (dcSSc), with skin lesions occurring proximal to the elbows and knees and with frequent visceral involvement. Although autoantibodies have been detected in the serum of patients with SSc and are helpful in the diagnosis and evaluation of the prognosis, the role of B lymphocytes in the pathogenesis of SSc is still poorly defined (2, 3) .
Circulating B lymphocytes from SSc patients differ from those from healthy controls by the presence of increased proportions of naive B cells and decreased numbers of memory B cells and plasma cells (4) . In addition, signaling alterations, including overexpression of both CD19 and CD21, two activating coreceptors of the B cell antigen receptor, have been detected both in the TSK-1 mouse model of SSc and in naive and memory B lymphocytes from patients with SSc. Moreover, the activation receptors CD80, CD86, and CD95 are up-regulated in memory B cells from SSc patients, suggesting their participation in the pathogenic process (4) .
High levels of BAFF have been measured in the serum of SSc patients, as well as overexpression of BAFF receptor at the surface of peripheral B cells from the same patients (5) . BAFF acting through the NF-kB pathway promotes B cell survival and participates in autoreactive B cell differentiation (6) . B cell infiltrates have also been detected in the dermis of SSc patients (7, 8) , and serum levels of interleukin-6 (IL-6) have been shown to be increased and to correlate with the extent of skin fibrosis both in humans with SSc and in the TSK-1 mouse model (9, 10) . IL-6 stimulates collagen secretion by fibroblasts and might therefore be an intermediate for fibroblast activation (11) .
Recent studies in which a chimeric anti-CD20 monoclonal antibody was used to deplete B cells, showed that this treatment allowed for the improvement of skin fibrosis and prevented the loss of pulmonary function in patients with SSc (12) . In a prospective randomized trial in which the IL-6 receptor (IL-6R) was targeted with tocilizumab, there was a promising effect of this treatment on skin involvement (13, 14) .
In the present study, we found abnormal phenotype patterns of peripheral B lymphocytes in patients with SSc, notably between those with lcSSc and those with dcSSc. We also identified increased cytokine production leading to fibroblast activation.
PATIENTS AND METHODS
Patients. Peripheral blood was obtained from 90 patients with SSc who fulfilled the American College of Rheumatism (ACR)/European League Against Rheumatism (EULAR) criteria for the diagnosis of SSc (15) and whose cases were followed at Cochin Hospital in the Department of Internal Medicine. The clinical characteristics of the study patients are available upon request from the corresponding author. Skin thickening in areas solely distal to the elbows and knees, with or without facial involvement, was defined as lcSSc. Skin thickening proximal as well as distal to the elbows and knees, with or without facial or truncal involvement, was defined as dcSSc (16) . Patients evaluated during the first 12 months after the first non-Raynaud's phenomenon symptom of SSc were defined as having early SSc. Peripheral blood was obtained from 30 healthy blood donors (controls) whose samples were included at the Etablissement Français du Sang (St. Antoine Hospital, Paris, France).
All patients and healthy controls gave written informed consent. Sera and peripheral blood mononuclear cells were collected with the approval of the ethics committee of the Groupe Hospitalier Piti e-Salpêtrière. The study conforms to the principles outlined in the Declaration of Helsinki. The work was performed within the D epartement Hospitalo-Universitaire, Autoimmune and Hormonal Diseases.
Fibroblast culture and functional studies. Biopsies of involved skin of 4 patients with SSc were performed. Normal human dermal fibroblasts were cultured from skin biopsy samples obtained from 4 healthy controls. Biopsy specimens were cut into small pieces and seeded into petri dishes and then into 175-cm 2 plastic flasks. Patients and healthy control fibroblasts were grown at 378C in Dulbecco's modified Eagle's medium (DMEM; Gibco) with 10% heat-inactivated fetal calf serum (FCS; Eurobio) in an atmosphere containing in 5% CO 2 .
At the third passage, fibroblasts from healthy controls or SSc patients were plated in 96-well plates at a concentration of 5 3 10 4 cells/ml. After 24 hours, fibroblasts were synchronized by replacing the FCS-supplemented DMEM with DMEM without FCS. After 24 hours of synchronization, media were replaced with FCS-supplemented DMEM with or without 8 representative supernatants of B lymphocytes obtained from 4 healthy controls or 4 patients with dcSSc (performed in triplicate). After 3 days of culture, the viability of fibroblasts was measured using a Colorimetric Cell Viability Kit III (XTT) from (PromoKine), proliferation was quantified using a bromodeoxyuridine cell proliferation enzyme-linked immunosorbent assay (Roche), and indirect immunofluorescence of Ki-67 was evaluated using antiKi-67 antibody (Abcam) and fluorescein isothiocyanate-coupled anti-rabbit secondary antibody (Jackson ImmunoResearch). Collagen content was quantified after 5 days of culture using a Sircol assay kit (Biocolor) according to the manufacturer's protocol.
Real-time polymerase chain reaction (PCR) was performed using 2.5 3 10using an RNeasy Mini kit (Qiagen) according to the manufacturer's protocol and then quantified using NanoVue (GE Healthcare Life Science). Four hundred nanograms of total RNA was retrotranscripted in complementary DNA (cDNA) using an iScript cDNA synthesis kit (Bio-Rad) and following the manufacturer's protocol. Expression of mRNA for a-smooth muscle actin (a-SMA), type I collagen, Snail, and vimentin was quantified in comparison to b 2 -microglobulin as the housekeeping gene. Realtime PCR was performed using a Power SYBR Green quantitative PCR (qPCR) kit on a StepOnePlus Real-Time PCR system (Applied Biosystems). Primers were obtained from Eurogentec (list of primers available upon request from the corresponding author).
Immunohistochemical study. Immunohistochemistry was performed on paraffin-embedded lung samples: 4-mm sections were dewaxed and rehydrated progressively. EDTA buffer (pH 9.0) or citrate buffer (pH 6.0) was used for antigen retrieval; endogenous peroxidase was quenched with hydrogen peroxide. Sections were blocked with 5% bovine serum albumin and incubated for 32 minutes with polyclonal antibody against CD20 (reference BSB5195; Bio SB) or CD69 (reference ab202909; Abcam), as recommended by the manufacturer. After incubation with a biotinylated secondary antibody, detection was performed with horseradish peroxidase-streptavidin and diaminobenzidine solution.
Statistical analysis. All analyses were carried out using GraphPad Prism 6 software, with 4 levels of statistical significance: P , 0.05, P , 0.01, P , 0.001, and P , 0.0001. Nonparametric tests, including the Mann-Whitney U test, were used for 2-group independent comparisons. Correlations of protein expression were performed using Spearman's correlation coefficient. Comparisons between fibroblast responses to B lymphocyte stimulation were analyzed using paired t-tests.
RESULTS
Differential peripheral B lymphocyte maturation in patients with SSc. The overall number of B cells and T cells was similar between healthy controls and SSc patients, despite a larger dispersal of T cells, which was mainly observed in patients with lcSSc (data available upon request from the corresponding author). Similarly, B lymphocyte subpopulation counts, including naive cells, effector memory cells, Breg cells, and plasmablasts, were equivalent among the healthy control, total SSc, dcSSc, and lcSSc patient groups (Figure 1 ). In contrast, the proportion of IgD-CD271 memory B lymphocytes was significantly decreased in patients with SSc as compared to healthy controls (P 5 0.04) (Figure 1) , with a similar distribution between SSc subsets. An additional differential proportion of marginal zone B cells was found between the dcSSc and lcSSc subgroups, but not between the total SSc group versus healthy controls. Specific analysis of mature B (Bm) cells showed the IgD-CD381 early Bm5 subpopulation as a predominantly decreased memory B cell subset, irrespective of SSc subset origin (P 5 0.001) (data available upon request from the corresponding author).
Activated peripheral B lymphocytes from SSc patients. Patients with SSc exhibited increased proportions of B lymphocytes expressing activation markers CD95 (P 5 0.0004), CD69 (P 5 0.002), and CD86 (P 5 0.001) as compared to healthy controls ( Figure 2A ). Similar results were obtained when the mean fluorescence intensity was quantified (data available upon request from the corresponding author). We also identified a B cell subpopulation expressing both CD69 and CD95 in SSc patients that was absent in healthy controls (P 5 0.0002) ( Figure 2B ). Interestingly, subpopulations expressing CD69 were correlated with those expressing CD95 in SSc The percentages of CD951 B cells were higher in patients with early lcSSc as compared to patients without early lcSSc (P 5 0.0027) ( Figure 2D ). In contrast, the proportion of peripheral CD691 B lymphocytes was higher in patients with early dcSSc as compared to those without early dcSSc (P 5 0.048). Furthermore, when we analyzed these 2 activation markers in combination, the percentage of CD691CD951 B cells was higher in early SSc patients than in those without early SSc (P , 0.0001). No associations between other activation markers were found for the SSc patients and the healthy controls.
The proportions of cells expressing CD86 differed significantly between dcSSc and lcSSc patients (P 5 0.0007) as well as for cells expressing CD5 (P 5 0.03) (Figure 2A ). CD86 and CD5 B cell subsets were not associated with autoantibody status (data not shown). Since these 2 receptors play a critical role in the B lymphocyte/T lymphocyte synapse, we investigated potential correlations between the proportions of CD51 and CD861 B lymphocytes and the proportions of Th1 (CD31CD41IFNg1), Th2 (CD31CD41IL-41), Th9 (CD31CD41IL-91), and Th17 (CD31CD41IL-17A1) cells (data available upon request from the corresponding author). No correlation of the percentage of CD51 or CD861 cells with these T cell subsets was found, except for a correlation between CD86 and the percentage of Th2 cells. Similar results were obtained when patients with dcSSc and lcSSc were analyzed separately.
In contrast, the proportions of cells expressing the inhibitory receptors CD22, CD32, and CD72 did not differ significantly between healthy controls and SSc patients, except for the comparison of CD321 cells between dcSSc and lcSSc subsets (P 5 0.02) ( Figure 3A) . Regarding membrane expression, B lymphocytes from SSc patients showed increased levels of the constitutively expressed activating coreceptor CD20 as compared to those from healthy controls (P 5 0.001), whereas no significant variation was found for the expression of the inhibitory receptors CD22, CD32, or CD72 or of HLA-DR (data available upon request from the corresponding author). Concerning the crosstalk of B cells with the microenvironment, a slight decrease in BAFF receptor (BR3)-expressing cells was detected in SSc patients as compared to healthy controls (P 5 0.04); however, this difference was not significant at the cellular level (data available upon request from the corresponding author). It is noteworthy that a remarkable increase in the populations expressing either IL-6R (P 5 0.01) or IL-21R (P 5 0.02) was observed in SSc patients versus controls, with major differences for IL-21R expression between dcSSc and lcSSc patients (P , 0.0001) regarding both subpopulation percentages ( Figure 3B ) and mean fluorescence intensity (data available upon request from the corresponding author).
In order to identify clinical manifestations of SSc that could be associated with B cell subsets, expression of activation markers and receptors were evaluated in the presence or absence of pulmonary arterial hypertension (PAH), interstitial lung disease (ILD), arthralgia (joint), and digital ulcers (data available upon request from the corresponding author). There was an increased proportion of B cells expressing CD86, which showed a slight association with PAH and digital ulcers in patients with SSc, while an increased subpopulation of CD951 B cells was associated with arthralgias. More interestingly, patients with either arthralgias or PAH with or without ILD had increased proportions of B cells expressing the IL-6R. For these 2 late manifestations of SSc, similar proportions of B lymphocytes expressing IL-6R were observed, which allowed us to discriminate between patients with PAH and/ or ILD and those without documented pulmonary involvement, who had a lower proportion of peripheral IL-6R1 B cells (data available upon request from the corresponding author).
Overall, we found no significant difference in B cell phenotypes based on autoantibody specificity (data not shown).
Detection of B lymphocytes in the lungs of patients with SSc-associated PAH. We performed immunostaining in lung samples from 3 patients with SSc-associated PAH and 3 healthy controls (normal lung tissue from patients with non-small cell lung carcinoma). In patients with SSc, a number of lymphoid follicles (mostly near bronchioles/ small airways) were observed, whereas only scattered B lymphocytes were seen in the lung parenchyma of the control subjects, as assessed by anti-CD20 immunostaining. In lymphocyte-rich areas, scattered CD691 cells were observed, whereas only faint staining of sparse cells was seen in control subjects (data available upon request from the corresponding author).
Consistency between phenotype characteristics of peripheral B cells and higher production of IL-6 and TGFb in SSc patients. A major increase in IL-6-producing cells was seen in SSc patients as compared to healthy controls (P , 0.0001) ( Figure 4A ). This difference was also found for both IgD1IL-61CD27-naive B cells (1:2 ratio; P , 0.0001) and IgD-IL-61CD271 memory B cells (1:1.8 ratio; P 5 0.0003) but not for marginal-zone or double-negative effector B cells (data not shown). We further analyzed the intracellular staining of IL-6 in both T lymphocytes (defined as CD271CD19-cells) and monocytes (using forward scatter/side scatter parameters in CD19-CD27-cells) (data available upon request from the corresponding author). No difference in the percentages of IL-61 T cells was observed in patients with SSc versus healthy controls, whereas a decreased proportion of monocytes expressed IL-6 in SSc patients as compared to healthy controls (data available upon request from the corresponding author). Thus, in patients with SSc, we identified B cells as the main source of IL-6 as compared to T lymphocytes and monocytes, which was not the case in healthy controls (data available upon request from the corresponding author).
We also investigated IL-10 and TGFb (Figures 4B and C) production by purified B lymphocytes after 3 days of culture with or without CpG stimulation. The number of IL-10-producing B cells did not differ significantly between the various samples under these conditions, and their phenotype corresponded to CD191 CD24 high CD271 / -CD38 high , predominantly CD5-(data available upon request from the corresponding author). More interestingly, peripheral B cells isolated from patients with SSc expressed increased proportion of TGFb1CD191 B lymphocytes as compared to healthy controls, even in the absence of further stimulation of Toll-like receptor 9 through incubation with CpG (P 5 0.0002) ( Figure 4C ). TGFb-expressing B lymphocytes were CD191CD5-CD24 low CD271CD38 high both in healthy controls and in patients with SSc, and did not overlap with IL-101 B lymphocytes (data available upon request from the corresponding author).
Secretion of higher amounts of IL-6 and TGFb and lower amounts of IL-10 by stimulated B cells from SSc patients. We detected higher levels of IL-6 in the serum of SSc patients as compared to healthy controls (P 5 0.01) ( Figure 5A ). No significant differences in the levels of IL-10 or TGFb were found ( Figure 5A ). Interestingly, purified B cells obtained from SSc patients and incubated for 3 days with CpG or for 4 hours with a mix of phorbol myristate acetate (PMA)/ionomycin secreted increased amounts of IL-6, whereas those from healthy controls remained low (P 5 0.0007) ( Figure 5B). We also detected slightly increased concentrations of IL-10 in B cell supernatants from the SSc patients as compared to the healthy controls after cell stimulation with PMA/ionomycin (P 5 0.01) ( Figure  5C ). Unexpectedly, while CpG stimulation promoted a weak increase in IL-10 secretion in SSc patients, a strong increase was observed in healthy control cells under these conditions. According to the increased proportion of TGFb-producing cells, we noted increased amounts of TGFb in the supernatants of CpGstimulated B cells from SSc patients as compared to healthy controls (P 5 0.001) ( Figure 5D ), while PMA/ ionomycin treatment did not significantly affect the release as compared to unstimulated cells (data available upon request from the corresponding author).
We found a correlation between the modified Rodnan skin thickness score and the concentration of TGFb in culture supernatants from B cells stimulated with CpG (r 5 0.60, P 5 0.04) ( Figure 5E ). A similar correlation between the modified Rodnan skin thickness score and the concentration of IL-6 in supernatants from B cells stimulated for 4 hours with PMA/ionomycin (r 5 0.71, P 5 0.01) was also noted, suggesting a potential profibrotic role of B lymphocytes in SSc patients.
Increased proliferative and fibrotic phenotype after in vitro stimulation of B lymphocytes derived from the dermal fibroblasts of healthy controls and SSc patients. Fibroblasts from healthy control subjects or from the involved skin of SSc patients were cultured for 3 days in the presence of supernatants from B cells obtained from healthy controls. We found no significant influence of culture on the metabolic activity ( Figure 6A ) or the proliferation rate of the fibroblasts, as assessed by immunofluorescence using Ki-67 labeling (data available upon request from the corresponding author). A random increase in viability was observed in all fibroblasts cultured in the presence of supernatants of B cells isolated from SSc patients, but the difference did not reach statistical significance (Figure 6A) . Prior stimulation of B cells from healthy controls or SSc patients did not provide any additional effect on viability. However, supernatants from CpG-or PMAstimulated SSc B cells significantly enhanced to various extents the proliferation of both healthy and SSc fibroblasts ( Figure 6B ). Consistent with their increased proliferation rate, fibroblasts from both healthy controls and SSc patients showed poor production of collagen in the presence of PMA-stimulated B cell supernatants from SSc patients as compared to those from healthy controls (Figure 6C) . When supernatants of CpG-stimulated purified B cells from healthy controls and SSc patients were used to stimulate fibroblasts in culture, collagen production was differentially increased in fibroblasts from both healthy controls and SSc patients ( Figure 6C ).
The expression of mRNA for a-SMA, type I collagen, Snail, and vimentin in stimulated fibroblasts from healthy controls and SSc patients was analyzed by qPCR and immunofluorescence. There was no consistent detection of a-SMA in fibroblasts from either healthy controls or SSc patients with either technique (data not shown). Figure 6 . Effect of purified B lymphocyte supernatants from healthy controls (HC) and patients with systemic sclerosis (SSc) on fibroblast proliferation and collagen production. Fibroblasts from 4 healthy controls and 4 patients with SSc were cultured for 3 days in the presence of supernatants from 3-day cultures of unstimulated (UNS) purified B lymphocytes, 3-day cultures of CpG-stimulated purified B lymphocytes, or 4-hour cultures of phorbol myristate acetate (PMA)/ionomycin-stimulated purified B lymphocytes from 4 healthy controls and 4 patients with diffuse SSc (nonautologous). A, Viability of fibroblasts was quantified using an XTT reduction assay kit, and the results were expressed as the percentage of XTT reduction in stimulated versus unstimulated fibroblasts. B, Proliferation of fibroblasts was quantified using a bromodeoxyuridine (BrdU) incorporation assay. Results were expressed as the percentage of BrdU incorporation by stimulated versus unstimulated fibroblasts. C, Collagen production by fibroblasts was quantified using a Sircol assay. Results were expressed as the percentage of collagen production by stimulated versus unstimulated fibroblasts. All experiments were performed twice, and the results were similar. Values are the mean 6 SD. * 5 P , 0.05; *** 5 P , 0.001, by paired t-test.
However, when fibroblasts from each group were stimulated with either CpG-or PMA/ionomycin-stimulated purified B cell supernatants from SSc patients, we observed increased expression of vimentin. Increased expression of mRNA for the transcription factor Snail and for type I collagen was also detected when fibroblasts from either healthy controls or SSc patients were stimulated with CpG-stimulated B cell supernatants from SSc patients. These increases were abrogated when supernatants were preincubated with anti-TGFb antibody (for CpG supernatants) or anti-IL-6R antibody (for PMA supernatants). Incubation with anti-TGFb antibody or anti-IL-6R antibody induced a drastic decrease in fibroblast proliferation without any difference in cell viability, thus reinforcing the potential pathophysiologic role of B lymphocytes in SSc (data available upon request from the corresponding author).
DISCUSSION
In the present work, we found evidence of an increased peripheral B cell subpopulation in SSc patients as compared to healthy controls that expresses both activation markers and cytokine receptors as well as high levels of intracellular IL-6 and TGFb. We also established that supernatants of B lymphocytes from SSc patients activate both normal and scleroderma fibroblasts at higher levels than do those from healthy controls.
In the SSc patients, we observed increased expression of CD86 and CD95 on B cells, together with a lower proportion of peripheral memory B cells, which is consistent with the results reported by Sato et al (4) . This decrease was found to be restricted to the early Bm5 memory peripheral B cell subpopulation, as previously noted in the peripheral blood of patients with Sj€ ogren's syndrome (17) . Interestingly, we found increased expression of CD69, IL-6R, and IL-21R on peripheral B lymphocytes from SSc patients, and we further correlated the increased proportions of CD691 cells with a decreased proportion of CD951 B lymphocytes. We also showed a major differential proportion of CD51, CD861, IL-6R1, or IL-21R1 B cells in the subgroups of patients with dcSSc and lcSSc. Indeed, patients with dcSSc had a higher proportion of these B cells as compared to both lcSSc patients and healthy controls. In contrast, both lcSSc and dcSSc patients showed increased proportions of CD691 and CD951 B cells as compared to healthy controls.
We found several correlations between B lymphocyte activation and disease duration in SSc patients, with higher expression of CD95 in the subgroup of patients with early lcSSc and an increased percentage of CD691 cells in patients with early dcSSc. In addition, we detected a double-positive subpopulation of CD691CD951 peripheral B cells in patients with early SSc, suggesting a possible link between B cell activation at an early stage of the disease and disease severity.
Of note, IL-6R expression was strongly associated with arthralgia, PAH, and/or ILD. There were similar proportions of B lymphocytes expressing IL-6R in patients with PAH and ILD. This finding allowed the discrimination of patients with versus those without lung involvement, the latter group exhibiting lower proportions of peripheral IL-6R1 B cells. In lung tissue from patients with SSc-associated PAH, we observed important numbers of B cells, with a number of lymphoid follicles, mostly in the vicinity of bronchioles/small airways, whereas only scattered B lymphocytes were seen in the lung parenchyma of control subjects, which provides further evidence implicating B cells in the lung involvement in SSc.
Taken together, our data support an activation profile of B lymphocytes in SSc patients, probably due to B cell receptor engagement via autoantigens, both for lcSSc and for dcSSc (18, 19) . Our data also suggest differential activation between dcSSc and lcSSc B lymphocytes, as was found for patients with PAH and/or ILD versus those without lung involvement. This differential activation could potentially occur through cytokine modulation, as suggested in a recent clinical study (20) . We found no correlation between B lymphocyte activation and autoantibody status, probably because they represent additional markers of disease activity/ severity. Since B cells from dcSSc patients with PAH and/or ILD are activated, these cells could be proposed as biomarkers.
Our findings also provide novel evidence of the production and secretion of cytokines. We identified both naive and memory B lymphocytes derived from SSc patients as major IL-6-secreting cells. However, a direct correlation between IL-6 levels in culture supernatants and IL-6R expression at the membrane of B lymphocytes was not observed. This result does not support an autocrine activating loop in SSc B lymphocytes, similar to the autostimulatory IL-6-driven B cell differentiation in patients with systemic lupus erythematosus (21) . The mechanisms leading to B lymphocyte overactivation might instead be due to the increased concentration of IL-6 in the serum of SSc patients versus healthy controls, as previously reported by Needleman et al (22) . Moreover, we showed that IL-6 levels in supernatants of purified B cells from SSc patients also correlate with the modified Rodnan skin thickness score, suggesting a critical role of B lymphocytes in the induction of fibrosis. Monocytes have been proposed as the unique immune cells producing IL-6 in patients with SSc (23, 24) . We provide herein new evidence of the characterization of IL-6-producing B lymphocytes in patients with SSc. These B lymphocytes might represent interesting treatment targets in these patients, since elevated levels of IL-6 in SSc patient sera have been shown to correlate with disease severity (9) .
In contrast to the results of a previous study, we found elevated TGFb production and release by peripheral B lymphocytes from SSc patients as compared to healthy controls, both under steady-state conditions and upon specific TLR stimulation (25) . These high levels of TGFb in supernatants of sorted B cells also correlated with the modified Rodnan skin thickness score, suggesting a role of B cells in the development of fibrosis. Indeed, Hasegawa et al (25) reported a lack of substantial increase in the release of TGFb by regulatory B cells, as well as activated T cells (26) or monocytes (27) in SSc patients, consistent with a nonimmune production of TGFb in those patients. In the present study, we identified a specific B lymphocyte subpopulation that secretes high levels of TGFb and exhibits a phenotype similar to those recently described in patients with graftversus-host disease (28) . The absence of IL-10 secretion by SSc B lymphocytes might also contribute to the loss of immunoregulation observed in SSc (29, 30) . Unfortunately, because of the limited amount of biologic samples available, we were not able to perform coculture experiments using B cells and T cells in order to evaluate these immunomodulatory roles or their potential interplay with T cells.
The pathogenic effects of the B lymphocytes in SSc remain poorly understood (2) . Recent reports have addressed interesting therapeutic targeting, both in mouse models and in open studies of limited populations of patients with SSc (31) (32) (33) (34) . Notably, François and colleagues (35) reported a direct implication of normal B cells in increased proliferation and extracellular matrix production by fibroblasts from healthy controls and SSc patients. In the present study, we demonstrated that supernatants of B lymphocytes purified from SSc patients induce fibroblast activation even in absence of direct cell-to-cell interaction or autoantibody secretion, but more as a consequence of an increased secretion of IL-6 and TGFb. We also found that supernatants of purified B lymphocytes with the higher level of TGFb (CpG supernatant) induced an increased expression of vimentin and the transcription factor Snail, 2 proteins that have been associated with the differentiation of fibroblasts into myofibroblasts (36) (37) (38) . Moreover, incubation with either anti-TGFb or anti-IL-6R antibodies induced a dramatic decrease in fibroblast proliferation without any difference in viability, which suggests an implication of these pathways in B cell/fibroblast crosstalk in SSc.
These data further underscore a possible interplay between B lymphocytes and fibroblasts through new secretory pathways that need to be further investigated in the pathogenesis of SSc. Furthermore, the recent results obtained with IL-6-targeted therapy in the mouse model of bleomycin-induced scleroderma and in patients with SSc highlight the prevalent role of this cytokine in the pathophysiology of SSc and reinforce interest in evaluating the IL-6 secretion capacity of peripheral B cells (22, 34, 39, 40) . Finally, these data also support interest in investigating the effects of IL-6-targeted therapy in patient with SSc, as the faSScinate study has shown interesting results using a monoclonal anti-IL-6R antibody (tocilizumab) (41) . Our study, based on a consistent number of phenotypically characterized SSc patients who did not receive treatment with glucocorticoid or immunosuppressive drugs, provides new insights into the functional implication of B lymphocytes in SSc.
In conclusion, clinical studies have shown promising results for anti-CD20-and anti-IL-6R-based therapies in patients with SSc (22, 40, 41) . We observed an increased activation of peripheral B cells in patients with dcSSc as compared to those with lcSSc. In vitro, B lymphocytes from SSc patients secreted high amounts of IL-6 and TGFb, which induced fibroblast proliferation, collagen secretion, and differentiation into myofibroblasts in fibroblasts from both healthy individuals and SSc patients. Our findings are the first to highlight differential B lymphocyte subpopulations in the two different SSc subtypes.
